Literature DB >> 15162823

In vitro chemosensitivity assays of retinoblastoma cells.

Motoko Inomata1, Akihiro Kaneko.   

Abstract

The use of chemotherapy in treating retinoblastoma is presently increasing in importance. Because of the rarity of this disease, excellent in vitro chemosensitivity assays are necessary, not only for individualized testing but also for the development of chemotherapy regimens. It is instructive for improving such assays to discuss in vitro chemosensitivitly tests of tumor cells from clinical specimens according to a cell biological perspective. This review will first summarize and discuss the technical problems encountered with several representative in vitro chemosensitivity tests on clinical specimens, including retinoblastoma. The second part of this review will summarize the results of chemosensitivity tests on retinoblastoma specifically.

Entities:  

Mesh:

Year:  2004        PMID: 15162823     DOI: 10.1007/s10147-003-0370-4

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  3 in total

Review 1.  The role of intravitreal chemotherapy for retinoblastoma.

Authors:  Fairooz P Manjandavida; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

2.  Intravitreal Melphalan Chemotherapy for Vitreous Seeds in Retinoblastoma.

Authors:  Yacoub A Yousef; Amal M Noureldin; Iyad Sultan; Rasha Deebajah; Maysa Al-Hussaini; Munir Shawagfeh; Mustafa Mehyar; Mona Mohammad; Imad Jaradat; Ibrahim AlNawaiseh
Journal:  J Ophthalmol       Date:  2020-01-24       Impact factor: 1.909

3.  Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma.

Authors:  Yacoub A Yousef; Mays Al Jboor; Mona Mohammad; Mustafa Mehyar; Mario D Toro; Rashed Nazzal; Qusai H Alzureikat; Magdalena Rejdak; Mutasem Elfalah; Iyad Sultan; Robert Rejdak; Maysa Al-Hussaini; Ibrahim Al-Nawaiseh
Journal:  Front Pharmacol       Date:  2021-07-12       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.